2374-03-0

Basic information

• Product Name: 4-Amino-3-hydroxybenzoic acid
• Synonyms: BENZOIC ACID, 4-AMINO-3-HYDROXY-;4-AMINO-3-HYDROXYBENZOIC ACID;3-HYDROXY-4-AMINOBENZOIC ACID;4-AMINO-3-HYDROXYBENZOIC ACID 97%;3-Hydroxy PABA;4-Amino-3-hydroxybenzoic acid,98%;3-hydroxy-4-AMino acid;4-Carboxy-2-hydroxyaniline, 2-Amino-5-carboxyphenol
• CAS NO: 2374-03-0
• Molecular Formula: C₇H₇NO₃
• Molecular Weight: 153.14
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Carboxylic Acids;Phenyls & Phenyl-Het;Carboxylic Acids;Phenyls & Phenyl-Het;Aromatic Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 2374-03-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 211-215 °C(lit.)
• Boiling Point: 385.7 °C at 760 mmHg
• Flash Point: 187.1 °C
• Appearance: Yellow-brown to brown/Crystalline Powder
• Density: 1.028
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.691
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.74±0.10(Predicted)
• Water Solubility: Soluble in chloroform, and aqeous ethanol, water (Partly miscible)
• BRN: 509859
• CAS DataBase Reference: 4-Amino-3-hydroxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-3-hydroxybenzoic acid(2374-03-0)
• EPA Substance Registry System: 4-Amino-3-hydroxybenzoic acid(2374-03-0)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 2374-03-0(Hazardous Substances Data)

Usage

Description

4-Amino-3-hydroxybenzoic acid, also known as protocatechuic acid, is a disubstituted benzoic acid with a chemical formula of C7H7NO4. It is a yellow-brown to brown crystalline powder that is soluble in water and slightly soluble in ethanol. This organic compound is known for its potential applications in the pharmaceutical industry due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
4-Amino-3-hydroxybenzoic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly sphingosine kinase inhibitors. These inhibitors play a crucial role in the development of drugs targeting various diseases, including cancer and inflammatory disorders.
As a building block for the development of novel drugs, 4-Amino-3-hydroxybenzoic acid contributes to the advancement of medical treatments by providing a structural foundation for the creation of new and effective pharmaceutical compounds.

InChI:InChI=1/C7H7NO3/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,9H,8H2,(H,10,11)

Upstream product

• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 150-13-0 4-amino-benzoic acid 
• 99-06-9 3-Carboxyphenol 

Downstream Products

• 861312-43-8 4-ethoxycarbonylamino-3-hydroxy-benzoic acid 
• 63435-16-5 3-hydroxy-4-aminobenzoic acid methyl ester 
• 87081-52-5 ethyl 4-amino-3-hydroxybenzoate 
• 861306-38-9 3-hydroxy-4-ureido-benzoic acid 
• 58123-77-6 3-hydroxy-4-iodobenzoic acid 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 34113-69-4 4-chloro-3-hydroxybenzoic acid 
• 107618-49-5 2-Hydroxy-2-phenyl-2H-1,4-benzoxazin-carbonsaeure-⁽⁷⁾ 
• 10098-40-5 4-acetamido-3-hydroxybenzoic acid 
• 160450-13-5 N-Boc-4-amino-3-hydroxybenzoic acid 
• 162252-43-9 3-Acetoxy-4-(acetylamino)benzoic acid 
• 860791-86-2 3-hydroxy-4-(1H-pyrrol-1-yl)benzoic acid 

Relevant articles and documents

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Methods for glycosylation inhibition using amino-benzoic acids and derivatives

The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Metabolism of benoxinate in humans

-